172 related articles for article (PubMed ID: 32871512)
1. Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
Gelibter S; Orrico M; Moiola L; Dagna L; Filippi M; Yacoub MR
J Neurol Sci; 2020 Nov; 418():117104. PubMed ID: 32871512
[No Abstract] [Full Text] [Related]
2. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Luo H; Bhatt H; Mohamad S; Uhrik E; Sen S; Mathew T; Yousif A
J Neurol; 2015 Mar; 262(3):779-80. PubMed ID: 25626723
[No Abstract] [Full Text] [Related]
3. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
Kogel AK; Gold R; Schneider R
J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
[No Abstract] [Full Text] [Related]
4. Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.
Abičić A; Adamec I; Habek M
Wien Med Wochenschr; 2023 Sep; 173(11-12):287-289. PubMed ID: 36920580
[TBL] [Abstract][Full Text] [Related]
5. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
6. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
Rastas C; Sirignano D; Barner A; Bruno-Murtha LA
J Neurol; 2019 Nov; 266(11):2867-2868. PubMed ID: 31350640
[No Abstract] [Full Text] [Related]
7. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
[TBL] [Abstract][Full Text] [Related]
8. Dimethyl fumarate associated lymphopenia in clinical practice.
Longbrake EE; Cross AH
Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
[No Abstract] [Full Text] [Related]
9. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
[No Abstract] [Full Text] [Related]
10. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
[TBL] [Abstract][Full Text] [Related]
11. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
[TBL] [Abstract][Full Text] [Related]
12. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
[TBL] [Abstract][Full Text] [Related]
13. Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: A case report.
Workel HH; Wolfhagen MJHM; Bouwhuis JW; Kloosterziel ME
Mult Scler Relat Disord; 2020 Jul; 42():102137. PubMed ID: 32408151
[TBL] [Abstract][Full Text] [Related]
14. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
[TBL] [Abstract][Full Text] [Related]
15. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate.
Algahtani H; Shirah B; Marghalani S; Algarni A
Mult Scler Relat Disord; 2019 Feb; 28():155-158. PubMed ID: 30597324
[TBL] [Abstract][Full Text] [Related]
16. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Capone F; Ferraro E; Motolese F; Di Lazzaro V
J Neurol; 2021 Sep; 268(9):3132-3134. PubMed ID: 33611610
[No Abstract] [Full Text] [Related]
19. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8
Anagnostouli MC; Velonakis G; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34049996
[No Abstract] [Full Text] [Related]
20. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]